With the first official biosimilar closer to reaching the U.S. market, strategies for marketing the lower-cost biologics are evolving. Debate at the Pharmaceutical Strategy Conference showcased differing views about how best to position biosimilars to patients, physicians and payers.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?